Pfizer pushes oncology results at ASCO, reigniting debate over how much the data should lift its valuation

Pfizer is using this year’s ASCO meeting to underline the clinical momentum behind two oncology therapies, as the company’s investors and analysts continue to debate how much the newest Phase 3 results should matter for valuation.

According to a report published by Yahoo Finance, Pfizer presented long-term findings from Phase 3 studies for BRAFTOVI in patients with BRAF V600E-mutated metastatic colorectal cancer, and for TALZENNA in patients with HRR-mutated metastatic prostate cancer. The outcomes were framed around survival benefits, a category of results that typically carries more weight than short-term response measures in oncology drug development and reimbursement discussions.

BRAFTOVI, which is the brand name for encorafenib, targets a specific genetic driver in colorectal cancer defined by the BRAF V600E mutation. In metastatic colorectal cancer, this subgroup can have limited options after standard therapy, and long-term survival data can influence both clinicians’ adoption and payers’ willingness to cover expensive targeted treatments.

TALZENNA is Pfizer’s brand name for talazoparib, a PARP inhibitor used in cancers that carry particular DNA repair defects. HRR stands for homologous recombination repair, a pathway involved in repairing DNA damage. In HRR-mutated metastatic prostate cancer, PARP inhibitors are positioned as a way to exploit tumor vulnerabilities, and long-term survival endpoints are often key to establishing durability.

The ASCO spotlight also comes as investors seek clarity on Pfizer’s broader oncology strategy and its ability to sustain growth through late-stage product updates. With many large pharma companies facing patent-cycle and competitive pressures, the market tends to scrutinize whether incremental survival improvements translate into meaningful expansion of treated populations or stronger pricing outcomes over time.

Even when long-term results are promising, the valuation question usually hinges on details that are not always fully captured in early reporting. The Yahoo Finance write-up, for example, emphasizes survival gains and the existence of long-term data presented at ASCO, but it does not provide granular information in the portion of coverage available here such as hazard ratios, absolute survival improvements, subgroup breakouts, or whether the results will support new label expansions in the near term.

For shareholders, the debate can also center on what the company might do next operationally: whether Pfizer plans to pursue additional indications or line-of-therapy expansions, how it expects clinicians to incorporate the data into treatment algorithms, and how competitive alternatives in colorectal and prostate cancer could affect uptake. Those choices determine whether clinical improvements convert into future sales growth, not just scientific validation.

What to watch next is whether Pfizer follows the ASCO presentations with more detailed disclosures, including publication-level statistics and regulatory plans. Investors will also look for evidence of durability across meaningful patient subgroups, and for guidance on how these oncology results fit into Pfizer’s financial outlook for 2026 and beyond. Until those specifics emerge, the market’s reaction is likely to remain divided between confidence in survival indicates and skepticism about how quickly they can flow into revenue.